Product Name: CMGA Antibody
Species Reactivity: Human
Tested Applications: IF, IHC-P, WB
Applications: For WB starting dilution is: 1:1000For IHC-P starting dilution is: 1:10~50For IF starting dilution is: 1:10~50For FACS starting dilution is: 1:10~50
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight: 51 kDa
Immunogen: This CMGA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 376-404 amino acids from the C-terminal region of human CMGA.
Host Species: Rabbit
Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.
Physical State: Liquid
CAS NO.: 1197300-24-5
Product: TGR5 Receptor Agonist
Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.
Concentration: 0.5 mg/ml
Storage Conditions: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Chromogranin-A, CgA, Pituitary secretory protein I, SP-I, Vasostatin-1, Vasostatin I, Vasostatin-2, Vasostatin II, EA-92, ES-43, Pancreastatin, SS-18, WA-8, WE-14, LF-19, AL-11, GV-19, GR-44, ER-37, CHGA
Accession NO.: P10645
Protein Ino: 215274270
Official Symbol: CHGA
Geneid: 1113
Background: The protein encoded by this gene is a member of thechromogranin/secretogranin family of neuroendocrine secretoryproteins. It is found in secretory vesicles of neurons andendocrine cells. This gene product is a precursor to threebiologically active peptides; vasostatin, pancreastatin, andparastatin. These peptides act as autocrine or paracrine negativemodulators of the neuroendocrine system. Other peptides, includingchromostatin, beta-granin, WE-14 and GE-25, are also derived fromthe full-length protein. However, biological activities for thesemolecules have not been shown.
PubMed ID:http://aac.asm.org/content/36/8/1699.abstract
